Table 3.
Analysis of factors that may affect the survival of patients with metastatic colorectal carcinoma receiving FOLFOX‐4 (n = 166)
| Characteristics | P‐values (univariate) | P‐values (multivariate) | HR | 95% CI |
|---|---|---|---|---|
| TSER 28‐bp polymorphism | ||||
| 2R/3R + 3R/3R vs 3R/3R | 0.06 | NA | NA | NA |
| GSTP1‐105 status | ||||
| Ile/Ile vs Ile/Val + Val/Val | 0.04 | 0.01 | 2.45 | 1.30–4.62 |
| ERCC1‐118 genotype | ||||
| T/T+T/C vs C/C | 0.03 | <0.01 | 3.15 | 1.89–5.23 |
| XPD‐751 status | ||||
| Lys/Gln vs Lys/Lys | 0.02 | <0.01 | 4.41 | 2.51–7.75 |
| Any risk genotype | ||||
| Presence vs absence | <0.01 | <0.01 | 5.73 | 2.22–14.78 |
Risk genotypes: GSTP1‐105 Ile/Ile, ERCC1‐118 C/T or T/T, and XPD‐751 Lys/Gln. 95% CI, 95% confidence interval for Cox hazard ratio; HR, Cox hazard ratio; NA, not analyzed.